Results 151 to 160 of about 2,083,027 (293)

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug

Arthritis Care &Research, EarlyView.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie, Timothy Beukelman, Nicholas P. McCormick, Jeffrey R. Curtis   +3 more
wiley   +1 more source

Abstracts from the VIII International Meeting of the Iberoamerican Academy of Oral Pathology and Medicine. Isla Margarita : Venezuela, 5-8 October 2009. Comunicaciones Orales [PDF]

, 2010
Iberoamerican Academy of Oral Pathology and Medicine
core  

Unilateral Facial Swelling as the Inaugural Sign of Anti-NPX2 Dermatomyositis: A Diagnostic Challenge in Oral Medicine. [PDF]

Case Rep Dent
Tilotta F, Le Vayer H, Bory O, Morbieu C, Radoi L.   +4 more
europepmc   +1 more source

The need for integrated research autopsies in the era of precision oral medicine. [PDF]

J Am Dent Assoc, 2023
Fernandes Matuck B, Ferraz da Silva LF, Warner BM, Byrd KM.   +3 more
europepmc   +1 more source

Oral Medicine: a retrospective analysis of patient profiles, diagnoses, and referral patterns in Mexico City. [PDF]

Med Oral Patol Oral Cir Bucal
Figueroa-Ramos AM, Anaya-Saavedra G, Irigoyen-Camacho ME, Mosqueda-Taylor A.   +3 more
europepmc   +1 more source

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

Arthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya, Sandra G. Williams, Raphael A. Kirou, Marissa Lightbourne, Rebecca J. Brown   +4 more
wiley   +1 more source

Brazilian oral medicine and oral pathology: international scientific collaborations. [PDF]

Med Oral Patol Oral Cir Bucal
Ferreira LM, Nascimento JP, Trezena S, Maia-Lima MP, Sobral LF, Alencar AM, -Martelli DR, Lopes MA, Pires FR, Martelli-Júnior H.   +9 more
europepmc   +1 more source

Assessing Tele-Oral Medicine in Saudi Arabia: A Cross-Sectional Study on Specialists' Experiences and Effectiveness in Oral Healthcare. [PDF]

Healthcare (Basel), 2023
Akeel S, Almazrooa S, Ali SA, Alhindi NA, Alhamed S, Felemban OM, Mansour G, Sabbahi D, Binmadi N, Mawardi H.   +9 more
europepmc   +1 more source

Prevalence of Systemic Lupus Erythematosus in Australia, 2010–2022: A Population‐Based Study Using Linked National Administrative Health Data

Arthritis Care &Research, Accepted Article.
Objectives Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition, with widely varying global prevalence estimates. Frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the US or UK at 19‐39 per 100,000 as opposed to 65‐97 per 100,000.
Lucinda Roper, Rachel Black, Joanna Tieu, Winnie Chen, Matthew Parker, Catherine Hill, Natasha Nassar, Mandana Nikpour   +7 more
wiley   +1 more source

How Oral Medicine Practice Is Reported: A Scoping Review of 114,971 Patients. [PDF]

Oral Dis
Barcellos Calderipe C, Borges Kirschnick L, Cardoso Soares A, Uchoa Vasconcelos AC, Ajudarte Lopes M, Simon Treister N, Santos-Silva AR.   +6 more
europepmc   +1 more source